Low business R&D a major threat to the European knowledge-based economy

European Commission presents a new publication on Europe's position in research and innovation. The "Key figures 2007 on Science, Technology and Innovation" shows that R&D intensity (R&D expenditure as % of GDP) in Europe has stagnated since the mid-nineties, while major competitors such as Japan, China or South Korea have been able to increase substantially their R&D effort, shaping a world where knowledge is more evenly distributed than ever before. Moreover, the R&D investment deficit against the US has remained constant over recent years. In particular, the low level of business R&D in the EU remains worrying. Key Figures 2007 shows that differences in the industrial structure of the EU compared to countries such as the US are the main cause for this low level of business R&D, with the EU having a smaller high-tech industrial sector, which usually has much higher levels of R&D spending. The new actions taken in Europe since 2005 in the context of the revised Lisbon Strategy need to be implemented if Europe is to successfully face this challenge.

"Knowledge is a key component of competitiveness" said European Science and Research Commissioner Janez Potočnik. "If our businesses are to be at the leading edge in the future, they need to invest in knowledge now. And governments need to put in place the appropriate measures to help them do so."

Since the last Key Figures in 2005, policy-makers have launched new initiatives at both EU and Member State level in order to boost the "Europe of Knowledge": The ambitious Seventh Framework Programme (FP7) has been adopted and is now underway with a substantially higher budget than its predecessor, FP6. Member States have made new and far-reaching commitments within the framework of the renewed Lisbon strategy by setting future R&D intensity targets. The recently published ERA Green Paper has launched a wide-ranging debate on the future orientations of the European Research Area (ERA).

Key Figures 2007 presents data and statistics on science, technology and innovation up to 2005, thus predating these recent initiatives and renewed commitments. It shows however that these recent policy developments are now more than ever needed, for at least five reasons:

  • The EU is part of a globalised world where knowledge is more evenly distributed than ever before. High competition on this level requires the EU to adapt and make the ERA more attractive to the rest of the world. The Key Figures 2007 show that countries like China already act as strong competitors in the globalised knowledge-based economy.
  • The report shows that EU R&D intensity has stagnated since the mid-nineties. In 2005, only 1.84% of GDP was spent on R&D in EU-27 and it still remains at a lower level than in the US, Japan or South Korea. Also new emerging economies such as China are rapidly catching-up. If current trends last, China will have caught up with the EU by 2009 in terms of R&D intensity. However, high R&D-intensive EU Member States such as Austria, Germany, Finland and Denmark show that it is possible to maintain and increase R&D intensity above 2% and even 3% of GDP.
  • Over 85% of the R&D intensity gap between the EU and its main competitors is caused by differences in business sector R&D financing. The low level of private R&D expenditure in Europe in comparison with the US is mostly due to differences in industrial structure and to the smaller size of the high-tech industry in the EU.
  • Regarding research excellence, although the EU is the world's largest producer of scientific knowledge, the impact of European science is lower than that of the US. Europe lags behind the US in all scientific disciplines in terms of citation impact scores and highly-cited publications. Also, EU universities are very much underrepresented at the top of a ranking based on bibliometric indicators of the world's largest universities. In addition, the linkage between technology (patented inventions) and the science base is much weaker in the EU than in the US. Europe has a difficulty in breaking through in new high-tech industries.
  • Even though private sector funds are a notable part of R&D, the public sector still has a major role to play. Public R&D funding in the EU must be sustained in order for private R&D activities to develop further and grow on a solid science base. The Key Figures 2007 reveal that high R&D intensity can be achieved when high contributions from the private sector go hand in hand with high levels of public funding. For those economies that are catching up, government funding of R&D is critical for creating and developing S&T capabilities.
For further information, please visit:
http://ec.europa.eu/invest-in-research/monitoring/statistical01_en.htm

Most Popular Now

Philips and Medtronic Advocacy Partnersh…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Medtronic Neurovascular, a leading innovator in neurovascular therapies, today announced a strategic advocacy partnership. Delivering timely stroke...

Wearable Cameras Allow AI to Detect Medi…

A team of researchers says it has developed the first wearable camera system that, with the help of artificial intelligence (AI), detects potential errors in medication delivery. In a test whose...

New AI Tool Predicts Protein-Protein Int…

Scientists from Cleveland Clinic and Cornell University have designed a publicly-available software and web database to break down barriers to identifying key protein-protein interactions to treat with medication. The computational tool...

AI for Real-Rime, Patient-Focused Insigh…

A picture may be worth a thousand words, but still... they both have a lot of work to do to catch up to BiomedGPT. Covered recently in the prestigious journal Nature...

New Research Shows Promise and Limitatio…

Published in JAMA Network Open, a collaborative team of researchers from the University of Minnesota Medical School, Stanford University, Beth Israel Deaconess Medical Center and the University of Virginia studied...

G-Cloud 14 Makes it Easier for NHS to Bu…

NHS organisations will be able to save valuable time and resource in the procurement of technologies that can make a significant difference to patient experience, in the latest iteration of...

Start-Ups will Once Again Have a Starrin…

11 - 14 November 2024, Düsseldorf, Germany. The finalists in the 16th Healthcare Innovation World Cup and the 13th MEDICA START-UP COMPETITION have advanced from around 550 candidates based in 62...

Hampshire Emergency Departments Digitise…

Emergency departments in three hospitals across Hampshire Hospitals NHS Foundation Trust have deployed Alcidion's Miya Emergency, digitising paper processes, saving clinical teams time, automating tasks, and providing trust-wide visibility of...

MEDICA HEALTH IT FORUM: Success in Maste…

11 - 14 November 2024, Düsseldorf, Germany. How can innovations help to master the great challenges and demands with which healthcare is confronted across international borders? This central question will be...

A "Chemical ChatGPT" for New M…

Researchers from the University of Bonn have trained an AI process to predict potential active ingredients with special properties. Therefore, they derived a chemical language model - a kind of...

Siemens Healthineers co-leads EU Project…

Siemens Healthineers is joining forces with more than 20 industry and public partners, including seven leading stroke hospitals, to improve stroke management for patients all over Europe. With a total...

MEDICA and COMPAMED 2024: Shining a Ligh…

11 - 14 November 2024, Düsseldorf, Germany. Christian Grosser, Director Health & Medical Technologies, is looking forward to events getting under way: "From next Monday to Thursday, we will once again...